Industry Overview

Asia-Pacific prostate cancer diagnostic and therapeutic market was valued at $5,914.1 million in 2025 and is projected to reach $14,951.9 million by 2035, growing at a CAGR of 9.8% during the forecast period (2026–2035). The rising incidence of prostate malignancies across several Asia-Pacific countries continues to expand the demand for advanced diagnostic and therapeutic interventions. Ageing demographics, particularly the growing population above 65 years, have increased the clinical burden and reinforced the need for early detection and long-term disease management strategies. Broader adoption of prostate-specific antigen testing, multiparametric MRI, and molecular imaging technologies has strengthened diagnostic accuracy and facilitated earlier clinical intervention. In parallel, the introduction of next-generation androgen receptor inhibitors, radioligand therapies, and minimally invasive surgical techniques has improved treatment outcomes and extended survival expectations. Public healthcare funding support, structured screening initiatives, and strong reimbursement frameworks in major Asia-Pacific economies have enhanced patient access to innovative therapies. Ongoing clinical research, strategic collaborations between academic institutions and biopharmaceutical companies, and regulatory encouragement for precision oncology solutions continue to support sustained market expansion.

Market Dynamics

Rising Disease Burden and Structured Screening Programs

The steady increase in prostate cancer incidence across Asia-Pacific remains a central growth driver for the diagnostic and therapeutic market. A significant proportion of the male population is entering higher-risk age brackets, leading to a sustained rise in screening volumes, confirmatory diagnostics, and long-term treatment demand. Organized screening initiatives, improved referral pathways, and expanded use of prostate-specific antigen testing have enhanced early detection rates. Clinical guidelines issued by regional oncology associations promote risk-adapted screening and standardized treatment algorithms, strengthening procedural consistency across healthcare systems. Greater awareness among patients and primary care physicians has reduced diagnostic delays, increasing case identification at earlier stages. This structured clinical approach directly elevates demand for imaging platforms, biopsy systems, pathology services, and curative as well as disease-control therapies.

Advancement in Precision Diagnostics and Targeted Therapeutics

Technological progress in imaging, molecular diagnostics, and targeted drug development is accelerating market expansion. Wider adoption of multiparametric MRI, PSMA-PET imaging, genomic profiling, and AI-assisted pathology has improved staging precision and patient stratification. These tools enable clinicians to select individualized treatment pathways, supporting the uptake of next-generation androgen receptor inhibitors, radioligand therapies, and minimally invasive surgical interventions. Regulatory approvals for innovative agents and expanding reimbursement coverage across major Asia-Pacific economies have strengthened commercial adoption. Pharmaceutical investment in late-stage clinical trials and label expansions continues to broaden therapeutic options for metastatic and castration-resistant disease segments. This alignment between diagnostic accuracy and therapy selection reinforces sustained revenue growth across both diagnostic and treatment segments.

Market Segmentation

• Based on the diagnostic technique, the market is segmented into Prostate-Specific Antigen (PSA) Test, Digital Rectal Examination (DRE), Prostate Biopsy, and Imaging Techniques.

• Based on therapeutics, the market is segmented into Hormonal Therapy, Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy, and Surgery.

Growing Clinical Demand Driven by Demographic Shift and Early Diagnosis

The expansion of the elderly male population across Asia-Pacific has led to a sustained rise in prostate cancer prevalence, directly increasing demand for diagnostic and therapeutic services. Higher life expectancy has extended the period of clinical risk, resulting in greater screening uptake and follow-up procedures. National cancer control programs and standardized diagnostic pathways have strengthened early detection rates. Increased utilization of prostate-specific antigen testing, targeted biopsies, and advanced imaging modalities has improved identification of clinically significant cases. Earlier diagnosis supports curative treatment interventions, including surgery and radiation therapy, thereby expanding procedural volumes. The consistent inflow of newly diagnosed patients ensures stable demand across hospitals, specialty clinics, and oncology centers.

Technological Innovation and Expanding Therapeutic Options

Rapid advancements in imaging systems, molecular diagnostics, and targeted drug development are reshaping the treatment landscape. Adoption of multiparametric MRI and PSMA-based imaging has enhanced staging accuracy and treatment planning. Precision medicine approaches, including genomic profiling, enable tailored therapy selection for localized and advanced disease stages. The introduction of novel androgen receptor pathway inhibitors, radioligand therapies, and minimally invasive surgical techniques has improved clinical outcomes and broadened treatment eligibility. Regulatory support for innovative oncology products and structured reimbursement mechanisms across Asia-Pacific healthcare systems facilitate commercial uptake. Continuous investment by pharmaceutical and medical device companies sustains product development pipelines, reinforcing long-term market growth.

Regional Outlook

Asia-Pacific prostate cancer diagnostic and therapeutic market is further divided by countries, including China, Japan, South Korea, India, Australia & New Zealand, ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, and others), and the Rest of Asia-Pacific.

Market Players Outlook

The major companies operating in the Asia-Pacific prostate cancer diagnostic and therapeutic market include F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Johnson & Johnson, AstraZeneca plc, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In January 2026, Telix Pharmaceuticals announced that the first patient has been dosed in a Phase 3 registration trial of TLX591-Px (Illuccix), a PSMA PET imaging agent, in Japanese patients with recurrent prostate cancer. This trial aims to support future marketing approval in Japan and strengthens the company’s clinical footprint in the Asia Pacific region’s nuclear medicine and precision diagnostics space.

• In July 2025, Cyclotek signed its first contract development and manufacturing (CDMO) agreement for a novel radionuclide therapy targeting prostate cancer in Australia. The deal focuses on producing a terbium-161 based radiopharmaceutical for clinical trials, illustrating growing regional capacity in advanced targeted radiotherapy development and trial support across Asia Pacific.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the Asia-Pacific prostate cancer diagnostic and therapeutic market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.